← Human Trials & Peer-Reviewed Studies
Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trial.
Plain-language guide to PMID 29458928 (2018): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 125 patients.
Key Facts
- PMID
- 29458928
- Journal
- Complementary therapies in medicine
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Aucoin M et al. (12 authors)
- DOI
- 10.1016/j.ctim.2017.09.011
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Many patients with depression fail to achieve remission after several consecutive treatments.
Who Took Part
The study group was 125 patients.
The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults.
Due to slow recruitment during the first season, amendments were made.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and pilot study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
Outcomes measured included depression severity, serum vitamin D levels and safety.
Three additional tertiary psychiatric clinics were also added as trial sites.
What Was Measured
Topics PubMed links to this paper include Antidepressive Agents, Depression, Epidemiologic Research Design and Vitamin D.
The authors tagged it with the keywords Clinical trial design and Obstacles.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 125 patients.
The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (Complementary therapies in medicine), a journal based in Scotland.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.